>Mercado mundial de amaurosis congénita de Leber, por tipo de enfermedad (tipo infantil, tipo juvenil y otros), tipo (terapia y diagnóstico), usuario final (hospitales, clínicas especializadas, centros quirúrgicos ambulatorios, atención médica domiciliaria y otros), canal de distribución (licitación directa y ventas minoristas) Tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado
El mercado mundial de la amaurosis congénita de Leber está impulsado por factores como el aumento de la prevalencia de enfermedades crónicas como la diabetes y los trastornos gastrointestinales, un número creciente de nuevos actores y la popularidad de las bombas de infusión en los servicios de atención domiciliaria, que aumentan su demanda, así como el aumento de la inversión en investigación y desarrollo, lo que conduce al crecimiento del mercado. Actualmente, se están llevando a cabo varios estudios de investigación, lo que se espera que cree una ventaja competitiva para que los fabricantes desarrollen nuevos e innovadores tratamientos y terapias para la amaurosis congénita de Leber, lo que se espera que brinde varias otras oportunidades en el mercado de la amaurosis congénita de Leber. Sin embargo, se espera que las estrictas regulaciones gubernamentales sobre la aprobación y los errores del dispositivo durante la terapia de infusión obstaculicen el crecimiento.
El informe de mercado global de amaurosis congénita de Leber proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un informe de analista, nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado. La escalabilidad y la expansión comercial de las unidades minoristas en los países en desarrollo de varias regiones y la asociación con proveedores para la distribución segura de productos de máquinas y medicamentos son los principales impulsores que impulsaron la demanda del mercado en el período de pronóstico.
El mercado mundial de amaurosis congénita de Leber es favorable y tiene como objetivo reducir la progresión de la enfermedad. Data Bridge Market Research analiza que el mercado mundial de amaurosis congénita de Leber crecerá a una tasa compuesta anual del 4,8 % durante el período de pronóstico de 2022 a 2029.
|
Métrica del informe |
Detalles |
|
Período de pronóstico |
2022 a 2029 |
|
Año base |
2021 |
|
Años históricos |
2020 (Personalizable para 2019 - 2014) |
|
Unidades cuantitativas |
Ingresos en millones de USD, precios en USD |
|
Segmentos cubiertos |
Por tipo de enfermedad (infantil, juvenil y otras), tipo (terapia, diagnóstico), usuario final (hospitales, clínicas especializadas, centros quirúrgicos ambulatorios , atención médica domiciliaria y otros), canal de distribución (licitación directa y ventas minoristas) |
|
Países cubiertos |
Por país (EE. UU., Canadá, México, Alemania, Francia, Italia, Reino Unido, España, Países Bajos, Rusia, Suiza, Turquía, Austria, Noruega, Hungría, Lituania, Irlanda, Polonia, Resto de Europa, Japón, China, India, Corea del Sur, Australia, Singapur, Malasia, Tailandia, Indonesia, Filipinas, Vietnam, Resto de Asia-Pacífico, Brasil, Argentina, Perú, Resto de Sudamérica, Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto, Resto de Medio Oriente y África) |
|
Actores del mercado cubiertos |
Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy (una subsidiaria de Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc., entre otros. |
Dinámica del mercado mundial de amaurosis congénita de Leber
Conductores
- Aumento de la incidencia y prevalencia de enfermedades de la retina mediadas por el gen rpe65
Las distrofias retinianas hereditarias (DRH) representan un grupo genéticamente diverso de enfermedades progresivas y debilitantes para la vista. Los pacientes adultos y pediátricos con pérdida de visión debido a DRH causada por mutaciones bialélicas en el gen del epitelio pigmentario de la retina de 65 kDa (RPE65) suelen recibir un diagnóstico clínico de retinitis pigmentosa (RP) y amaurosis congénita de Leber (LCA).
La amaurosis congénita de Leber (LCA) es un trastorno ocular que afecta principalmente a la retina. La LCA se caracteriza por un deterioro visual grave desde el nacimiento o los primeros meses de vida, movimientos oculares errantes o nistagmo, respuestas pupilares deficientes a la luz, signo óculodigital (tocar, frotar y/o presionar los ojos) y electrorretinograma de campo completo (ERG) indetectable o muy anormal. La LCA suele heredarse como una enfermedad genética autosómica recesiva.
- Aumento de productos en desarrollo y ensayos clínicos
La innovación continua para el tratamiento de enfermedades hereditarias de la retina y el trastorno de amaurosis congénita de Leber tiene el potencial de impactar positivamente en el mercado, ya que el tamaño del mercado aumentará cuando estos productos hayan sido aprobados en el mercado global. Debido a que no hay tratamientos farmacológicos para la LCA, los principales actores del mercado están continuamente innovando el tratamiento o invirtiendo en I+D para el tratamiento. Varios ensayos clínicos en curso están reclutando en todo el mundo para encontrar el mecanismo de las enfermedades para el tratamiento.
Oportunidades
- Aumentan las iniciativas gubernamentales para abordar la amaurosis congénita de Leber
Según la OMS, la prevalencia de las enfermedades respiratorias inducidas por el virus de la inmunodeficiencia humana (IRD) monogénicas es de aproximadamente 1 de cada 40.000 recién nacidos en todo el mundo. Para prevenirlas, los gobiernos de varios países del mundo han tomado iniciativas.
The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the global leber congenital amaurosis market.
Restraints/Challenges
The cost of the product plays a major factor in the market. In the inherited retinal diseases market, it is generally observed that the cost of the products is highly sophisticated, need to be precise, and other specifications increase the product's cost.
The high cost of the treatment is due to the various checkpoints of the treatment along with the use of high-tech modalities to perform such treatment procedures.
However, the hospital care further adds to the cost of the leber congenital amaurosis. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with leber congenital amaurosis treatment and diagnosis is expected to restrain the global leber congenital amaurosis market growth.
Whereas the European Medicines Agency does not. Gene therapy products are regulated by FDA’s Center for Biologics Evaluation and Research (CBER). FDA requires the submission of an IND before initiating clinical studies, and an approved biologics license application (BLA) to market the product in the United States. The regulatory framework for the development and manufacturing of gene therapy products comprises regulations and guidance documents, including the interpretation of these governing documents by regulators.
However, every country is bounded by the guidelines regulated by different authorities which are expected to act as a challenge to the growth of the global leber congenital amaurosis market.
Recent Developments
- In September 2021, Gyroscope Therapeutics Limited clinical-stage gene therapy company focused on diseases of the eye, announced positive interim data from the ongoing open-label Phase I/II clinical trial of its investigational one-time gene therapy, GT005, in people with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- In January 2020, Allergan launched SkinMedica Instant Bright Eye Cream, a refreshing eye treatment that hydrates, brightens, and helps visibly firm the appearance of the delicate skin around the eyes. The product is designed to immediately improve the appearance of the eyes and continues reducing the visible signs of aging and fatigue over time including dark circles, fine lines, and creepiness of upper eyelids.
Global Leber Congenital Amaurosis Market Segmentation
Global leber congenital amaurosis market is categorized into disease type, type, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Disease Type
- Infantile Type
- Juvenile Type
- Others
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type & others
Type
- Diagnosis
- Therapy
On the basis by type, the global leber congenital amaurosis market is segmented into diagnosis and therapy. Diagnosis segment is further segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further segmented into clinical eye examination, visual field test, retail imaging, and electro physiological tests. Clinical diagnosis is sub-segmented into electrophysiological tests, retinal imaging, visual field test and clinical eye examination. Electrophysiology tests is subsegmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Retinal imaging is subsegmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO) and adaptive optics (AO) imaging and conventional color fundus imaging. Visual field tests is sub-segmented into computerized visual field tests and manual field test. Clinical examination is sub-segmented into slit lamp, indirect ophthalmoscopy, refraction test and dilation exam. Therapy segment is further segmented into gene therapy, retinal therapy, neuroprotective agents, and others. Gene therapy is further segmented into luxturna and others. Neuroprotective agents are further segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, and others.
End User
- Hospitals
- Specialty clinics
- Ambulatory surgical centers
- Home healthcare
- Others
On the basis of end user, the global leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
Distribution Channel
- Retail Sales
- Direct Tender
On the basis of distribution channel, the global leber congenital amaurosis market is segmented into retail sales, direct tender.
Leber Congenital Amaurosis Market Regional Analysis/Insights
The leber congenital amaurosis market is analyzed and market size insights and trends are provided by country, disease type, type, end user, and distribution channel as referenced above.
The countries covered in the leber congenital amaurosis market report are U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa.
Europe is expected to dominate due to increase in technological advancement in the developing areas.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación del mercado que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como el análisis de la cadena de valor ascendente y descendente, las tendencias técnicas y el análisis de las cinco fuerzas de Porter, los estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales se consideran al proporcionar un análisis de pronóstico de los datos del país.
Panorama competitivo y análisis del mercado de amaurosis congénita de Leber
El panorama competitivo del mercado global de amaurosis congénita de Leber proporciona detalles de los competidores. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento del producto, la amplitud y la extensión del producto y el dominio de la aplicación. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en el mercado de amaurosis congénita de Leber.
Invitae Corporation, Spark Therapeutics, Inc., LKC Technologies, CENTOGENE NV, Optos, Metrovision, Blue Print Genetics Oy (una subsidiaria de Quest Diagnostics), CD Genomics, ProQR Therapeutics, OCUGEN, INC., MeiraGTx Limited, Coave Therapeutics, IVERIC bio, Inc., Atsena Therapeutics, Editas Medicine, Eluminex Biosciences, Okuvision, Astellas Pharma Inc., Allergan, agtc, Gyroscope Therapeutics Limited, SparingVision, Kubota Pharmaceutical Holdings Co. Ltd., REGENXBIO Inc., entre otros.
Metodología de la investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con tamaños de muestra grandes. Los datos del mercado se analizan y estiman utilizando modelos estadísticos y coherentes del mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Aparte de esto, los modelos de datos incluyen la cuadrícula de posicionamiento de proveedores, el análisis de la línea de tiempo del mercado, la descripción general y la guía del mercado, la cuadrícula de posicionamiento de la empresa, el análisis de la participación de mercado de la empresa, los estándares de medición, el análisis global frente al regional y el análisis de la participación de los proveedores. Solicite una llamada de un analista en caso de tener más consultas.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL LEBER CONGENITAL AMAUROSIS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PIPELINE ANALYSIS FOR GLOBAL LEBER CONGENTIAL AMAUROSIS MARKET
4.2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS
4.3 PESTEL ANALYSIS
4.4 PORTERS FIVE FORCES
5 EPIDEMIOLOGY
6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
6.2 RESTRAINTS
6.2.1 LACK OF QUALIFIED PROFESSIONALS
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE
6.3 OPPORTUNITIES
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS
7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE
7.1 OVERVIEW
7.2 INFANTILE TYPE
7.3 JUVENILE TYPE
7.4 OTHERS
8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE
8.1 OVERVIEW
8.2 THERAPY
8.2.1 GENE THERAPY
8.2.1.1 LUXTURNA
8.2.2 RETINAL PROSTHETIC
8.2.3 NEUROPROTECTIVE AGENTS
8.2.3.1 VITAMIN A PALMITATE
8.2.3.2 DOCOSAHEXAENOIC ACID
8.2.3.3 LUTEIN
8.2.3.4 OTHERS
8.2.4 OTHERS
8.3 DIAGNOSIS
8.3.1 CLINICAL DIAGNOSIS
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
8.3.1.1.2 DARK ADAPTOMETRY (DA)
8.3.1.2 RETINAL IMAGING
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING
8.3.1.3 VISUAL FIELD TEST
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
8.3.1.3.2 MANUAL FIELD TEST
8.3.1.4 CLINICAL EYE EXAMINATION
8.3.1.4.1 SLIT LAMP
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY
8.3.1.4.3 REFRACTION TEST
8.3.1.4.4 DILATION EXAM
8.3.1.5 OTHERS
8.3.2 GENETIC DIAGNOSIS
9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALITY CLINICS
9.4 AMBULATORY SURGICAL CENTERS
9.5 HOME HEALTHCARE
9.6 OTHERS
10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 RETAIL SALES
10.2.1.1 HOSPITAL PHARMACIES
10.2.1.2 RETAIL PHARMACIES
10.2.1.3 OTHERS
10.3 DIRECT TENDER
11 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 CANADA
11.2.3 MEXICO
11.3 EUROPE
11.3.1 GERMANY
11.3.2 FRANCE
11.3.3 U.K.
11.3.4 RUSSIA
11.3.5 ITALY
11.3.6 SPAIN
11.3.7 NETHERLAND
11.3.8 SWITZERLAND
11.3.9 POLAND
11.3.10 TURKEY
11.3.11 AUSTRIA
11.3.12 HUNGARY
11.3.13 NORWAY
11.3.14 IRELAND
11.3.15 LITHUANIA
11.3.16 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 SOUTH KOREA
11.4.5 AUSTRALIA
11.4.6 SINGAPORE
11.4.7 THAILAND
11.4.8 INDONESIA
11.4.9 PHILIPPINES
11.4.10 MALAYSIA
11.4.11 VIETNAM
11.4.12 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 BRAZIL
11.5.2 ARGENTINA
11.5.3 PERU
11.5.4 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SOUTH AFRICA
11.6.2 SAUDI ARABIA
11.6.3 U.A.E
11.6.4 ISRAEL
11.6.5 EGYPT
11.6.6 KUWAIT
11.6.7 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 SPARK THERAPEUTICS, INC
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.1.4.1 EU AUTHORIZATION
14.2 OPTOS
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.2.4.1 PRODUCT APPROVAL
14.3 CD GENOMICS
14.3.1 COMPANY SNAPSHOT
14.3.2 COMPANY SHARE ANALYSIS
14.3.3 PRODUCT PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.4.5.1 COLLABORATION
14.5 LKC TECHNOLOGIES, INC
14.5.1 COMPANY SNAPSHOT
14.5.2 COMPANY SHARE ANALYSIS
14.5.3 PRODUCT PORTFOLIO
14.5.4 RECENT DEVELOPMENT
14.5.4.1 PRODUCT APPROVAL
14.5.5 PRODUCT APPROVAL
14.6 AGTC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.6.4.1 AGREEMENT
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.)
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 ASTELLAS PHARMA INC.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ATSENA THERAPEUTICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENT
14.1 CENTOGENE N.V.
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.10.4.1 PRODUCT LAUNCH
14.11 COAVE THERAPEUTICS
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 EDITAS MEDICINE
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.12.4.1 DATA & TRAIL DATA PRESENTATION
14.13 ELUMINEX BIOSCIENCES
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 GYROSCOPE THERAPEUTICS LIMITED
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENTS
14.15 INVITAE CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENTS
14.15.4.1 NEW FACILITY
14.15.4.2 EXPANSION
14.16 IVERIC BIO.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD.
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MEIRAGTX LIMITED
14.18.1 COMPANY SNAPSHOT
14.18.2 PRODUCT PORTFOLIO
14.18.3 RECENT DEVELOPMENT
14.19 METROVISION
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.19.3.1 FDA CLEARANCE APPROVAL
14.2 OCUGEN INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 OKUVISION
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENTS
14.21.3.1 APPROVAL
14.22 PROQR THERAPEUTICS
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 REGENXBIO INC.
14.23.1 COMPANY SNAPSHOT
14.23.2 REVENUE ANALYSIS
14.23.3 PRODUCT PORTFOLIO
14.23.4 RECENT DEVELOPMENTS
14.24 SPARINGVISION
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
Lista de Tablas
TABLE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 2 GLOBAL INFANTILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 GLOBAL JUVENILE TYPE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 GLOBAL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 GLOBAL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 GLOBAL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 GLOBAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 GLOBAL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 GLOBAL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 GLOBAL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 GLOBAL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 GLOBAL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 18 GLOBAL HOSPITALS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 GLOBAL SPECIALITY CLINICS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 GLOBAL AMBULATORY SURGICAL CENTERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 21 GLOBAL HOME HEALTHCARE IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 GLOBAL OTHERS IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 24 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 GLOBAL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 26 GLOBAL DIRECT TENDER IN LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 33 NORTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 34 NORTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 43 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 44 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 U.S. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 46 U.S. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 47 U.S. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 U.S. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 U.S. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 U.S. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 U.S. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 U.S. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 U.S. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 55 U.S. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 56 U.S. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 57 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 58 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 CANADA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 CANADA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 CANADA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 CANADA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 CANADA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 CANADA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 CANADA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 CANADA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 CANADA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 69 CANADA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 70 CANADA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 72 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 MEXICO THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 MEXICO GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 MEXICO NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 MEXICO DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 MEXICO CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 MEXICO RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 MEXICO ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 MEXICO VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 MEXICO CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 MEXICO LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 MEXICO RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 86 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 87 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 EUROPE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 EUROPE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 EUROPE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 EUROPE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 EUROPE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 EUROPE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 EUROPE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 EUROPE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 EUROPE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 98 EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 99 EUROPE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 100 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 101 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 GERMANY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 GERMANY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 GERMANY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 GERMANY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 GERMANY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 GERMANY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 GERMANY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 GERMANY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 110 GERMANY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 111 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 112 GERMANY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 113 GERMANY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 114 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 115 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 FRANCE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 FRANCE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 FRANCE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 FRANCE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 FRANCE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 FRANCE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 FRANCE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 123 FRANCE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 FRANCE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 126 FRANCE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 127 FRANCE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 128 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 129 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 U.K. THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 131 U.K. GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 132 U.K. NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 133 U.K. DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 U.K. CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 U.K. RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 U.K. ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 U.K. VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 138 U.K. CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 139 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 140 U.K. LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 141 U.K. RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 142 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 143 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 RUSSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 RUSSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 RUSSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 RUSSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 148 RUSSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 149 RUSSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 150 RUSSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 RUSSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 152 RUSSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 153 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 RUSSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 155 RUSSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 156 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 157 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 158 ITALY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 159 ITALY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 160 ITALY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 161 ITALY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 162 ITALY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 163 ITALY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 164 ITALY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 165 ITALY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 166 ITALY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 167 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 168 ITALY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 169 ITALY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 171 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 172 SPAIN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 173 SPAIN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 174 SPAIN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 175 SPAIN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 176 SPAIN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 177 SPAIN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 178 SPAIN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 179 SPAIN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 180 SPAIN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 181 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 182 SPAIN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 183 SPAIN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 184 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 185 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 186 NETHERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 187 NETHERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 188 NETHERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 189 NETHERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 190 NETHERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 191 NETHERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 192 NETHERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 193 NETHERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 194 NETHERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 195 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 196 NETHERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 197 NETHERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 198 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 199 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 200 SWITZERLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 201 SWITZERLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 202 SWITZERLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 203 SWITZERLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 204 SWITZERLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 205 SWITZERLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 206 SWITZERLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 207 SWITZERLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 208 SWITZERLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 209 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 210 SWITZERLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 211 SWITZERLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 212 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 213 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 214 POLAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 215 POLAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 216 POLAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 217 POLAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 218 POLAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 219 POLAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 220 POLAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 221 POLAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 222 POLAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 223 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 224 POLAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 225 POLAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 226 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 227 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 228 TURKEY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 229 TURKEY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 230 TURKEY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 231 TURKEY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 232 TURKEY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 233 TURKEY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 234 TURKEY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 235 TURKEY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 236 TURKEY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 237 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 238 TURKEY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 239 TURKEY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 240 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 241 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 242 AUSTRIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 243 AUSTRIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 244 AUSTRIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 245 AUSTRIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 246 AUSTRIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 247 AUSTRIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 248 AUSTRIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 249 AUSTRIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 250 AUSTRIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 251 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 252 AUSTRIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 253 AUSTRIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 254 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 255 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 256 HUNGARY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 257 HUNGARY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 258 HUNGARY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 259 HUNGARY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 260 HUNGARY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 261 HUNGARY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 262 HUNGARY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 263 HUNGARY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 264 HUNGARY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 265 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 266 HUNGARY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 267 HUNGARY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 268 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 269 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 270 NORWAY THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 271 NORWAY GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 272 NORWAY NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 273 NORWAY DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 274 NORWAY CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 275 NORWAY RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 276 NORWAY ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 277 NORWAY VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 278 NORWAY CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 279 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 280 NORWAY LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 281 NORWAY RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 282 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 283 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 284 IRELAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 285 IRELAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 286 IRELAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 287 IRELAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 288 IRELAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 289 IRELAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 290 IRELAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 291 IRELAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 292 IRELAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 293 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 294 IRELAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 295 IRELAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 296 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 297 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 298 LITHUANIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 299 LITHUANIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 300 LITHUANIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 301 LITHUANIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 302 LITHUANIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 303 LITHUANIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 304 LITHUANIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 305 LITHUANIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 306 LITHUANIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 307 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 308 LITHUANIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 309 LITHUANIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 310 REST OF EUROPE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 311 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 312 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 313 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 314 ASIA-PACIFIC THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 315 ASIA-PACIFIC GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 316 ASIA-PACIFIC NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 317 ASIA-PACIFIC DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 318 ASIA-PACIFIC CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 319 ASIA-PACIFIC RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 320 ASIA-PACIFIC ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 321 ASIA-PACIFIC VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 322 ASIA-PACIFIC CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 323 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 324 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 325 ASIA-PACIFIC RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 326 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 327 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 328 CHINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 329 CHINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 330 CHINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 331 CHINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 332 CHINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 333 CHINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 334 CHINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 335 CHINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 336 CHINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 337 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 338 CHINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 339 CHINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 340 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 341 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 342 JAPAN THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 343 JAPAN GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 344 JAPAN NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 345 JAPAN DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 346 JAPAN CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 347 JAPAN RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 348 JAPAN ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 349 JAPAN VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 350 JAPAN CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 351 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 352 JAPAN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 353 JAPAN RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 354 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 355 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 356 INDIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 357 INDIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 358 INDIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 359 INDIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 360 INDIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 361 INDIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 362 INDIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 363 INDIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 364 INDIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 365 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 366 INDIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 367 INDIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 368 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 369 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 370 SOUTH KOREA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 371 SOUTH KOREA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 372 SOUTH KOREA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 373 SOUTH KOREA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 374 SOUTH KOREA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 375 SOUTH KOREA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 376 SOUTH KOREA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 377 SOUTH KOREA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 378 SOUTH KOREA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 379 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 380 SOUTH KOREA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 381 SOUTH KOREA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 382 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 383 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 384 AUSTRALIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 385 AUSTRALIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 386 AUSTRALIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 387 AUSTRALIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 388 AUSTRALIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 389 AUSTRALIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 390 AUSTRALIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 391 AUSTRALIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 392 AUSTRALIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 393 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 394 AUSTRALIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 395 AUSTRALIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 396 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 397 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 398 SINGAPORE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 399 SINGAPORE GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 400 SINGAPORE NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 401 SINGAPORE DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 402 SINGAPORE CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 403 SINGAPORE RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 404 SINGAPORE ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 405 SINGAPORE VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 406 SINGAPORE CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 407 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 408 SINGAPORE LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 409 SINGAPORE RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 410 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 411 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 412 THAILAND THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 413 THAILAND GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 414 THAILAND NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 415 THAILAND DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 416 THAILAND CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 417 THAILAND RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 418 THAILAND ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 419 THAILAND VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 420 THAILAND CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 421 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 422 THAILAND LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 423 THAILAND RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 424 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 425 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 426 INDONESIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 427 INDONESIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 428 INDONESIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 429 INDONESIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 430 INDONESIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 431 INDONESIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 432 INDONESIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 433 INDONESIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 434 INDONESIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 435 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 436 INDONESIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 437 INDONESIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 438 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 439 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 440 PHILIPPINES THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 441 PHILIPPINES GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 442 PHILIPPINES NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 443 PHILIPPINES DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 444 PHILIPPINES CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 445 PHILIPPINES RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 446 PHILIPPINES ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 447 PHILIPPINES VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 448 PHILIPPINES CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 449 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 450 PHILIPPINES LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 451 PHILIPPINES RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 452 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 453 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 454 MALAYSIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 455 MALAYSIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 456 MALAYSIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 457 MALAYSIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 458 MALAYSIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 459 MALAYSIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 460 MALAYSIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 461 MALAYSIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 462 MALAYSIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 463 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 464 MALAYSIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 465 MALAYSIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 466 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 467 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 468 VIETNAM THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 469 VIETNAM GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 470 VIETNAM NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 471 VIETNAM DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 472 VIETNAM CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 473 VIETNAM RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 474 VIETNAM ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 475 VIETNAM VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 476 VIETNAM CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 477 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 478 VIETNAM LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 479 VIETNAM RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 480 REST OF ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 481 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 482 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 483 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 484 SOUTH AMERICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 485 SOUTH AMERICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 486 SOUTH AMERICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 487 SOUTH AMERICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 488 SOUTH AMERICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 489 SOUTH AMERICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 490 SOUTH AMERICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 491 SOUTH AMERICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 492 SOUTH AMERICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 493 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 494 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 495 SOUTH AMERICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 496 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 497 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 498 BRAZIL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 499 BRAZIL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 500 BRAZIL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 501 BRAZIL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 502 BRAZIL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 503 BRAZIL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 504 BRAZIL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 505 BRAZIL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 506 BRAZIL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 507 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 508 BRAZIL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 509 BRAZIL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 510 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 511 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 512 ARGENTINA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 513 ARGENTINA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 514 ARGENTINA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 515 ARGENTINA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 516 ARGENTINA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 517 ARGENTINA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 518 ARGENTINA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 519 ARGENTINA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 520 ARGENTINA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 521 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 522 ARGENTINA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 523 ARGENTINA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 524 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 525 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 526 PERU THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 527 PERU GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 528 PERU NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 529 PERU DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 530 PERU CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 531 PERU RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 532 PERU ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 533 PERU VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 534 PERU CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 535 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 536 PERU LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 537 PERU RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 538 REST OF SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 539 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 540 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 541 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 542 MIDDLE EAST AND AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 543 MIDDLE EAST AND AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 544 MIDDLE EAST AND AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 545 MIDDLE EAST AND AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 546 MIDDLE EAST AND AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 547 MIDDLE EAST AND AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 548 MIDDLE EAST AND AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 549 MIDDLE EAST AND AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 550 MIDDLE EAST AND AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 551 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 552 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 553 MIDDLE EAST AND AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 554 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 555 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 556 SOUTH AFRICA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 557 SOUTH AFRICA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 558 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 559 SOUTH AFRICA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 560 SOUTH AFRICA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 561 SOUTH AFRICA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 562 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 563 SOUTH AFRICA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 564 SOUTH AFRICA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 565 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 566 SOUTH AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 567 SOUTH AFRICA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 568 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 569 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 570 SAUDI ARABIA THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 571 SAUDI ARABIA GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 572 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 573 SAUDI ARABIA DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 574 SAUDI ARABIA CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 575 SAUDI ARABIA RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 576 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 577 SAUDI ARABIA VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 578 SAUDI ARABIA CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 579 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 580 SAUDI ARABIA LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 581 SAUDI ARABIA RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 582 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 583 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 584 U.A.E THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 585 U.A.E GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 586 U.A.E NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 587 U.A.E DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 588 U.A.E CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 589 U.A.E RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 590 U.A.E ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 591 U.A.E VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 592 U.A.E CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 593 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 594 U.A.E LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 595 U.A.E RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 596 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 597 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 598 ISRAEL THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 599 ISRAEL GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 600 ISRAEL NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 601 ISRAEL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 602 ISRAEL CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 603 ISRAEL RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 604 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 605 ISRAEL VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 606 ISRAEL CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 607 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 608 ISRAEL LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 609 ISRAEL RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 610 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 611 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 612 EGYPT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 613 EGYPT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 614 EGYPT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 615 EGYPT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 616 EGYPT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 617 EGYPT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 618 EGYPT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 619 EGYPT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 620 EGYPT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 621 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 622 EGYPT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 623 EGYPT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 624 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 625 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 626 KUWAIT THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 627 KUWAIT GENE THERAPY IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 628 KUWAIT NEUROPROTECTIVE AGENTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 629 KUWAIT DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 630 KUWAIT CLINICAL DIAGNOSIS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 631 KUWAIT RETINAL IMAGING IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 632 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 633 KUWAIT VISUAL FIELD TEST IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 634 KUWAIT CLINICAL EYE EXAMINATION IN LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 635 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 636 KUWAIT LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 637 KUWAIT RETAIL SALES IN LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 638 REST OF MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
Lista de figuras
FIGURE 1 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 2 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: END USER GRID
FIGURE 9 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SEGMENTATION
FIGURE 11 RISING GOVERNMENT AWARENESS PROGRAMS ABOUT THE INHERITED RETINAL DISEASE IS EXPECTED TO DRIVE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INFANTILE TYPE IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN 2022 & 2029
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET IN LEBER CONGENITAL AMAUROSIS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE GLOBAL LEBER CONGENITAL AMAUROSIS MARKET
FIGURE 16 PROPORTION OF RPE65 GENE MUTATION IN CLINICALLY DIAGNOSED LCA PATIENTS
FIGURE 17 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2021
FIGURE 18 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)
FIGURE 19 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 20 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 21 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2021
FIGURE 22 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 23 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 24 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 25 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2021
FIGURE 26 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 27 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 28 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 29 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 30 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 31 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 32 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY END USER, LIFELINE CURVE
FIGURE 33 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 34 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021)
FIGURE 35 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2022 & 2029)
FIGURE 36 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY REGION (2021 & 2029)
FIGURE 37 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 38 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 43 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 44 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 45 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 47 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 48 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 49 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 50 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 51 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 52 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 53 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 54 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 55 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 56 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 57 SOUTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 58 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: SNAPSHOT (2021)
FIGURE 59 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2021)
FIGURE 60 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 61 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 62 MIDDLE EAST AND AFRICA LEBER CONGENITAL AMAUROSIS MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 63 GLOBAL LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 64 NORTH AMERICA LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 65 EUROPE LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
FIGURE 66 ASIA-PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
